1800 Williams St., Suite 200 • Denver, CO 80218
Phone 303-388-4876 • Fax 303-336-2193 • Toll Free 1-800-891-7622

URL http://www.rockymountainbmt.com/clinical_trials/index.html

Clinical Trials

We are committed to developing innovative therapies for blood cancers, bone marrow diseases and disorders. Our cutting edge research insures our patients are receiving the most progressive therapies available.

• Acute Lymphocytic Leukemia (ALL)
• Acute Myeloid Leukemia (AML)
• Amyloidosis
• Aplastic Anemia
• Chronic Lymphocytic Leukemia (CLL)
• Chronic Myeloid Leukemia (CML)
• Hodgkin Lymphoma
• Multiple Myeloma
• Non-Hodgkin Lymphoma (NHL)

Acute Lymphocytic Leukemia (ALL)

Standard Treatments

• Total Body Irradiation with Cyclphosphamide Or Etoposide As Preparative Therapy For Autologous And Allogeneic Stem Cell Transplantation: Standard Care Treatment Protocol
  
  
  

Clinical Trials

• 1581 - Allogeneic Nonmyeloablative Hematopoietic Stem Cell Transplant for Patients with STI-571 Responsive Ph+ Acute Leukemia - Multi-Center Trial
  
  
  
• 1591 Campath - Alemtuzumab Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients with Hematologic Malignancies - A Multi-Center Trial
  
  
  
• 1938 - A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies A Multi-Center Trial
  
  
  
• 1959 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation For Patients With Hematologic Malignancies - A Multicenter Trial
  
  
  
• Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression after Conditioning with Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA Matched Family Donor Hematopoietic Cell Transplants
  
  
  
• Treatment Of Hematologic Malignancies With High-Dose Chemo-Radiotherapy Followed By Single-Unit Or Double-Unit Cord Blood Transplantation: A Phase II Study
  
  
  

Acute Myeloid Leukemia (AML)

Standard Treatments

• Total Body Irradiation with Cyclphosphamide Or Etoposide As Preparative Therapy For Autologous And Allogeneic Stem Cell Transplantation: Standard Care Treatment Protocol
  
  
  

Clinical Trials

• 1591 Campath - Alemtuzumab Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients with Hematologic Malignancies - A Multi-Center Trial
  
  
  
• 1938 - A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies A Multi-Center Trial
  
  
  
• 1959 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation For Patients With Hematologic Malignancies - A Multicenter Trial
  
  
  
• 1992 - A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplant Conditioning in Patients with Myelodysplastic Syndrome or Acute Myelogenous Leukemia
  
  
  
• Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression after Conditioning with Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA Matched Family Donor Hematopoietic Cell Transplants
  
  
  
• Treatment Of Hematologic Malignancies With High-Dose Chemo-Radiotherapy Followed By Single-Unit Or Double-Unit Cord Blood Transplantation: A Phase II Study
  
  
  

Amyloidosis

Standard Treatments

• A Treatment Guideline for High-Dose Melphalan with Autologous Hematopoietic Stem Cell Reconstitution for Primary Systemic Amyloidosis
  
  
  

Aplastic Anemia

Standard Treatments

• Cyclophosphamide and Antithymocyte Globulin, With or Without Total Body Irradiation, Followed By Allogeneic Hematopoietic stem Cell Transplantation For Severe Aplastic Anemia
  
  
  

Chronic Lymphocytic Leukemia (CLL)

Standard Treatments

• Total Body Irradiation with Cyclphosphamide Or Etoposide As Preparative Therapy For Autologous And Allogeneic Stem Cell Transplantation: Standard Care Treatment Protocol
  
  
  

Clinical Trials

• 1591 Campath - Alemtuzumab Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients with Hematologic Malignancies - A Multi-Center Trial
  
  
  
• 1938 - A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies A Multi-Center Trial
  
  
  
• 1959 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation For Patients With Hematologic Malignancies - A Multicenter Trial
  
  
  
• Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression after Conditioning with Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA Matched Family Donor Hematopoietic Cell Transplants
  
  
  

Chronic Myeloid Leukemia (CML)

Standard Treatments

• Total Body Irradiation with Cyclphosphamide Or Etoposide As Preparative Therapy For Autologous And Allogeneic Stem Cell Transplantation: Standard Care Treatment Protocol
  
  
  

Clinical Trials

• 1581 - Allogeneic Nonmyeloablative Hematopoietic Stem Cell Transplant for Patients with STI-571 Responsive Ph+ Acute Leukemia - Multi-Center Trial
  
  
  
• 1591 Campath - Alemtuzumab Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients with Hematologic Malignancies - A Multi-Center Trial
  
  
  
• 1938 - A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies A Multi-Center Trial
  
  
  
• 1959 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation For Patients With Hematologic Malignancies - A Multicenter Trial
  
  
  
• Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression after Conditioning with Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA Matched Family Donor Hematopoietic Cell Transplants
  
  
  
• Treatment Of Hematologic Malignancies With High-Dose Chemo-Radiotherapy Followed By Single-Unit Or Double-Unit Cord Blood Transplantation: A Phase II Study
  
  
  

Hodgkin Lymphoma

Standard Treatments

• Total Body Irradiation with Cyclphosphamide Or Etoposide As Preparative Therapy For Autologous And Allogeneic Stem Cell Transplantation: Standard Care Treatment Protocol
  
  
  
• Treatment of Non-Hodgkin Lymphoma with High-Dose Carmustine, Etoposide, Cytarabine, and Cyclophosphamide (BEAC) or Melphalan (BEAM) Followed by Autologous Peripheral Blood Progenitor Cells Standard Care Treatment Protocol
  
  
  

Clinical Trials

• 1591 Campath - Alemtuzumab Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients with Hematologic Malignancies - A Multi-Center Trial
  
  
  
• 1938 - A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies A Multi-Center Trial
  
  
  
• 1959 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation For Patients With Hematologic Malignancies - A Multicenter Trial
  
  
  
• Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression after Conditioning with Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA Matched Family Donor Hematopoietic Cell Transplants
  
  
  
• Treatment of Relapsed or Primary Refractory Hodgkin Lymphoma with High-Dose CBV Followed by Autologous Peripheral Blood Progenitor Cell Rescue
  
  
  

Multiple Myeloma

Standard Treatments

• High Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplant As Rescue Therapy for Multiple Myeloma
  
  
  
• Total Body Irradiation with Cyclphosphamide Or Etoposide As Preparative Therapy For Autologous And Allogeneic Stem Cell Transplantation: Standard Care Treatment Protocol
  
  
  

Clinical Trials

• 1591 Campath - Alemtuzumab Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients with Hematologic Malignancies - A Multi-Center Trial
  
  
  
• 1938 - A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies A Multi-Center Trial
  
  
  
• 1959 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation For Patients With Hematologic Malignancies - A Multicenter Trial
  
  
  
• Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression after Conditioning with Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA Matched Family Donor Hematopoietic Cell Transplants
  
  
  

Non-Hodgkin Lymphoma (NHL)

Standard Treatments

• Total Body Irradiation with Cyclphosphamide Or Etoposide As Preparative Therapy For Autologous And Allogeneic Stem Cell Transplantation: Standard Care Treatment Protocol
  
  
  
• Treatment of Non-Hodgkin Lymphoma with High-Dose Carmustine, Etoposide, Cytarabine, and Cyclophosphamide (BEAC) or Melphalan (BEAM) Followed by Autologous Peripheral Blood Progenitor Cells Standard Care Treatment Protocol
  
  
  

Clinical Trials

• 1591 Campath - Alemtuzumab Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients with Hematologic Malignancies - A Multi-Center Trial
  
  
  
• 1938 - A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies A Multi-Center Trial
  
  
  
• 1959 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation For Patients With Hematologic Malignancies - A Multicenter Trial
  
  
  
• Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression after Conditioning with Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA Matched Family Donor Hematopoietic Cell Transplants
  
  
  
• Treatment Of Hematologic Malignancies With High-Dose Chemo-Radiotherapy Followed By Single-Unit Or Double-Unit Cord Blood Transplantation: A Phase II Study
  
  
  
• Treatment of Non-Hodgkin Lymphoma with High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Followed by Allogeneic Marrow or Peripheral Blood Stem Cell Transplantation